Vical Gets $2.3M for Phase 3 Trial

Xconomy San Diego — 

San Diego’s Vical (NASDAQ: VICL), which specializes in developing DNA vaccines, says it received a $2.3 million payment from Japan’s AnGes MG to continue its work on a phase 3 trial of its Allovectin-7 vaccine for metastatic melanoma. Vical says it has received $17.6 million in total payments so far out of $22.6 million that AnGes pledged under their development agreement. Vical has been developing a variety of DNA vaccines, in which the expressed protein is an immunogen, immune system stimulant, or in the case of cardiovascular therapy, an angiogenic growth factor.